BenParkMDPhD(He/Him)

PubMed

• An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release.
  Brad A Davidson, Adam X Miranda, Sarah C Reed, Riley E Bergman, Justin D J Kemp, Anvith P Reddy, Morgan V Pantone, Ethan K Fox, R Dixon Dorand, Paula J Hurley, Sarah C...> ;Communications Biology. 2024 Apr 10
• Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data.
  Levente Lippenszky, Kathleen F Mittendorf, Zoltán Kiss, Michele L LeNoue-Newton, Pablo Napan-Molina, Protiva Rahman, Cheng Ye, Balázs Laczi, Eszter Csernai, Neha M Jai...> ;JCO Clinical Cancer Informatics. 2024 Feb 1
• Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
  Smith, K., Zhao, F., Mayer, I., Tevaarwerk, A., Garcia, S., Arteaga, C., Symmans, W., Park, B., Burnette, B., Makower, D., Block, M., Morley, K., Jani, C., Mescher, C....> ;Cancer. 2024 Jan 18
• 8 citations
  Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest.
  Reece Foy, Lisa Crozier, Aanchal U Pareri, Juan Manuel Valverde, Ben Ho Park, Tony Ly, Adrian T Saurin> ;Molecular Cell. 2023 Nov 16
• 1 citations
  Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospe...
  Meridith L Balbach, Alexander D Sherry, Brent N Rexer, Vandana G Abramson, Kenneth J Niermann, Corbin R Johnson, Ben Ho Park, Ingrid A Mayer, A Bapsi Chakravarthy> ;International Journal of Radiation Oncology, Biology, Physics. 2024 Apr 1
• 26 citations
  Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
  Susana Garcia-Recio, Toshinori Hinoue, Gregory L Wheeler, Benjamin J Kelly, Ana C Garrido-Castro, Tomas Pascual, Aguirre A De Cubas, Youli Xia, Brooke M Felsheim, Marn...> ;Nature Cancer. 2023 Jan 1
• 5 citations
  CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors.
  Sarah C Reed, Sarah Croessmann, Ben Ho Park> ;Clinical Cancer Research. 2023 Apr 14
• 3 citations
  Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge.
  Benjamin C Park, Seungyeon Jung, Jordan J Wright, Douglas B Johnson> ;The Oncologist. 2022 Dec 9
• 2 citations
  Immune checkpoint inhibitors and their impact on liver enzymes and attenuation.
  Benjamin C Park, Aaron X T Lee, Fei Ye, Isik Turker, Douglas B Johnson> ;BMC Cancer. 2022 Sep 20
• 7 citations
  Call for action: expanding global access to hereditary cancer genetic testing.
  Brittany Bychkovsky, Huma Q Rana, Foluso Ademuyiwa, Jennifer Plichta, Karen Anderson, Angélica Nogueira-Rodrigues, Cesar A Santa-Maria, Lan G Coffman, Carol Marquez, A...> ;The Lancet. Oncology. 2022 Sep 1
• 5 citations
  A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
  Kristin A Altwegg, Suryavathi Viswanadhapalli, Monica Mann, Dimple Chakravarty, Samaya Krishnan, Zexuan Liu, Junhao Liu, Uday P Pratap, Behnam Ebrahimi, John R Sanchez...> ;Cancer Research. 2022 Oct 17
• 4 citations
  Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition.
  Sm N Udden, Qian Wang, Sunil Kumar, Venkat S Malladi, Shwu-Yuan Wu, Shuguang Wei, Bruce A Posner, Sophie Geboers, Noelle S Williams, Yulun Liu, Jayesh K Sharma, Ram S ...> ;JCI Insight. 2022 Sep 8
• 28 citations
  Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
  N Lynn Henry, Mark R Somerfield, Zoneddy Dayao, Anthony Elias, Kevin Kalinsky, Lisa M McShane, Beverly Moy, Ben Ho Park, Kelly M Shanahan, Priyanka Sharma, Rebecca Sha...> ;Journal of Clinical Oncology. 2022 Sep 20
• 7 citations
  Targeting Metabolic Adaptations in the Breast Cancer-Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy.
  Qianying Zuo, Ayca Nazli Mogol, Yu-Jeh Liu, Ashlie Santaliz Casiano, Christine Chien, Jenny Drnevich, Ozan Berk Imir, Eylem Kulkoyluoglu-Cotul, Nicole Hwajin Park, Dav...> ;Molecular Cancer Research. 2022 Jun 3
• 4 citations
  Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
  Elaine M Walsh, Neha Mangini, John Fetting, Deborah Armstrong, Isaac S Chan, Roisin M Connolly, Katie Fiallos, Jennifer Lehman, Raquel Nunes, Dana Petry, Jeffrey Reyno...> ;Clinical Breast Cancer. 2022 Jun 1
• 6 citations
  Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer.
  Minetta C Liu, Matthew MacKay, Matthew Kase, Aneta Piwowarczyk, Christine Lo, Jeff Schaeffer, Justin D Finkle, Christopher E Mason, Nike Beaubier, Kimberly L Blackwell...> ;JCO Precision Oncology. 2022 Jun 1
• 15 citations
  Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
  Zheqi Li, Yang Wu, Megan E Yates, Nilgun Tasdemir, Amir Bahreini, Jian Chen, Kevin M Levine, Nolan M Priedigkeit, Azadeh Nasrazadani, Simak Ali, Laki Buluwela, Spencer...> ;Cancer Research. 2022 Apr 1
• 5 citations
  Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers.
  Shixiang Sun, Kristina Brazhnik, Moonsook Lee, Alexander Y Maslov, Yi Zhang, Zhenqiu Huang, Susan Klugman, Ben H Park, Jan Vijg, Cristina Montagna> ;The Journal of Clinical Investigation. 2022 Mar 1
• 3 citations
  A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach.
  Jessica A Lavery, Eva M Lepisto, Samantha Brown, Hira Rizvi, Caroline McCarthy, Michele LeNoue-Newton, Celeste Yu, Jasme Lee, Xindi Guo, Thomas Yu, Julia Rudolph, Shaw...> ;JCO Clinical Cancer Informatics. 2022 Feb 1
• 1 citations
  PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model.
  Karen Cravero, Morgan V Pantone, Dong Ho Shin, Riley Bergman, Rory Cochran, David Chu, Daniel J Zabransky, Swathi Karthikeyan, Ian G Waters, Natasha Hunter, D Marc Ros...> ;Oncotarget. 2022 Jan 1
• 20 citations
  Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.
  Samantha Brown, Jessica A. Lavery, Ronglai Shen, Axel Martin, Kenneth L. Kehl, Shawn M. Sweeney, Eva M Lepisto, Hira Rizvi, Caroline G. McCarthy, Nikolaus Schultz, Jer...> ;JAMA Oncology. 2021 Nov 4
• 7 citations
  Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute–Designated Comprehensive Cancer Center
  Neha Jain, Lauren Schmalz, Christopher G. Cann, Adara Holland, Travis J. Osterman, Katie Lang, Georgia L. Wiesner, Tuya Pal, Christine M. Lovly, Thomas Stricker, Chris...> ;The Oncologist. 2021 Nov 1
• 2 citations
  Reply to T. Shimoi et al and Y. Shimanuki et al.
  Ingrid A. Mayer, Fengmin Zhao, Carlos L. Arteaga, William Fraser Symmans, Ben Ho Park, Brian L. Burnette, Amye J. Tevaarwerk, Sofia F. Garcia, Karen L. Smith, Della F....> ;Journal of Clinical Oncology. 2021 Sep 23
• 20 citations
  Systemic inhibition of PTPN22 augments anticancer immunity
  Won Jin Ho, Sarah Croessmann, Jian-Ping Lin, Zaw Phyo, Soren Charmsaz, Ludmila Danilova, Aditya Mohan, Nicole Gross, Fangluo Chen, Jiajun Dong, Devesh Aggarwal, Yunpen...> ;The Journal of Clinical Investigation. 2021 Sep 1
• 1 citations
  Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
  Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath...> ;Clinical Cancer Research. 2021 Sep 1
• Join now to see all

Journal Articles

• High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients  
  Alhuqail AJ, Alzahrani A, Almubarak H, Al-Qadheeb S, Alghofaili L, Almoghrabi N, Alhussaini H, Park BH, Colak D, Karakas B., Breast Cancer Res Treat, 1/1/2018
• PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity  
  Croessmann S, Wong HY, Zabransky DJ, Chu D, Rosen DM, Cidado J, Cochran RL, Dalton WB, Erlanger B, Cravero K, Button B, Kyker-Snowman K, Hurley PJ, Lauring J, Park BH, Breast Cancer Res Treat, 1/1/2017
• Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board  
  Dalton B, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson E, S..., JCO Precision Oncology, 1/1/2017
• A single nucleotide polymorphism leading to a false allelic fraction by droplet digital PCR  
  Christenson ES, Dalton WB, Chu D, Waters I, Cravero K, Zabransky DJ, DeZern A, Park BH., Clin. Chem., 1/1/2017
• AACR Project GENIE: Powering Precision Medicine through an International Consortium  
  Cancer Discovery, 1/1/2017
• Liquid Biopsy: Unlocking the Potentials of Cell Free DNA  
  Chu D and Park BH., Virchows Archives., 1/1/2017
• Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercis...  
  VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P., Am J Surg Pathol., 1/1/2016
• A polycythemia vera JAK2 mutation masquerading as a germline cancer mutation in a patient with duodenal cancer  
  Lee J, Axilbund J, Dalton BD, Laheru D, Watkins S, Chu D, Cravero K, Button B, Kyker-Snowman K, Waters I, Gocke C, Lauring J and Park BH., The Journal of the National Comprehensive Cancer Network, 1/1/2016
• Circulating Tumor DNA�the Potential of Liquid Biopsies  
  Cravero K and Park BH, Curr Breast Cancer Rep, 1/1/2016
• Use of cell free DNA in breast oncology  
  Canzoniero JV and Park BH., BBA - Reviews on Cancer., 1/1/2016
• ESR1 mutations: Pi�ce de r�sistance  
  Button B and Park BH., Genes and Diseases, 1/1/2016
• Frequent BRAF V600E mutations in metanephric stromal tumor  
  Argani P, Lee J, Netto GJ, Zheng G, Tseh-Lin M, Park BH, Am J Surg Path, 1/1/2016
• Use of Biomarkers for the Assessment of Chemotherapy-induced Cardiac Toxicity  
  Christenson E., James T., Agrawal V., Park BH, Clinical Biochemistry, 1/1/2015
• Gene mutation profiling of breast cancers for clinical decision making: drivers and passengers in the cart before the horse  
  Stearns V and Park BH, JAMA Oncology, 1/1/2015
• Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramati...  
  VandenBussche C, Cimino-Mathews A, Park BH, Emens LA, TsangarisTN, Argani P., Am.J.Surg.Path., 1/1/2015
• Activating PIK3CA mutations induce an EGFR/ERK paracrine signaling axis in basal-like breast cancer  
  Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola N, Silva GO, Patel P, Brantley-Siede..., Molecular & Cellular Proteomics., 1/1/2015
• Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA  
  Valda Toro P, Erlanger B, Beaver JA, Cochran RL, VanDenBerg DA, Yakim E, Cravero K, Chu D, Zabransky DJ, Wong HY, Croessmann S, Parsons H, Hurley PJ, Lauring J, Park BH, Clin. Biochem., 1/1/2015
• Somatic alterations as the basis for resistance to targeted therapies  
  Blair B, Bardelli A, Park BH, The Journal of Pathology, 1/1/2014
• Plasma tumor DNA: On your mark-ers, get set, GO!  
  Wong HY, Park BH., Annals of Translational Medicine, 1/1/2014
• A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the miR-183-96-182 cluster  
  Li XL, Hara T, Choi Y, Subramanian M, Francis P, Bilke S, Walker RL, Pineda M, Zhu Y, Yan Y, Luo J, Wakefield LM, Brabletz T, Park BH, Sharma S, Chowdhury D, Meltzer P..., MolCellBio., 1/1/2014
• Analysis of BRCA2 loss-of-heterozygosity in tumor tissue using droplet digital PCR  
  Cochran RL, Cravero K, Chu D, Erlanger B, Valda Toro P, Beaver JA, Zabransky DJ, Wong HY, Cidado J, Croessmann S, Parsons H, Kim M, Wheelan SJ, Argani P and Park BH., Human Pathology, 1/1/2014
• The PIK3CA gene as a mutated target for cancer therapy  
  Croessmann S, Cidado J, Gustin JP, Cosgrove D, Park BH., Advances in Cancer Drug Targets, 1/1/2013
• TORn in Two Over Breast Cancer Drug Resistance  
  Cochran R, Lauring J, Park BH, Oncology, 1/1/2013
• Neural crest transcription factor Sox10 is preferentially expressed in triple negative and metaplastic breast carcinomas  
  Cimino-Mathews A, Subhawong AP, Elwood H, Nassar H, Sharma R, Park BH, Taube J, Illei PB, Argani P., Human Pathology, 1/1/2013
• GATA3 Expression in Breast Carcinoma: Utility in Triple Negative, Sarcomatoid and Metastatic Carcinomas  
  Cimino-Mathews A, Subhawong AP, Elwood H, Nassar H, Sharma R, Park BH, Taube J, Illei PB, Argani P, Human Pathology, 1/1/2013
• Join now to see all

Books/Book Chapters

• Genome Applications in Pathology 
  Chapter: Circulating cell-free DNA for molecular diagnostics and therapeutic monitoring 
  Hunter NB, Beaver JA and Park BH.SpringerEdition 2nd,2018
• Liquid Biopsies in Solid Tumors 
  Chapter: Circulating Free Tumor DNA (ctDNA): The Real-Time Liquid Biopsy 
  Page 105.0 - 118.0Kyker-Snowman K, Park BH.Springer2017
• Digital PCR Applied Protocols, Methods in Molecular Biology 
  Chapter: Detection of Cancer DNA in Plasma of Early Stage Breast Cancer Patients 
  Page 209.0 - 227.0Medford A, Gillani R and Park BH.Editors: Karlin-Neumann and Bizouarn.Springer2017
• Novel Biomarkers in the Continuum of Breast Cancer 
  Chapter: Circulating Plasma Tumor DNA 
  Page 259.0 - 276.0Parsons, H, Beaver J and Park BHEditors: Stearns.Springer2016
• Genome Applications in Biology 
  Chapter: Circulating cell-free DNA for molecular diagnostics and therapeutic monitoring 
  Page 85.0 - 97.0Beaver J, Park BH.Springer2015
• First Aid for the USMLE Step 2, Clinical Knowledge 
  Park BHMcGraw HillEdition Seve,2009
• Encyclopedia of Cancer 
  Chapter: PIK3CA Oncogene 
  Park BHEditors: M. Schwab.SpringerEdition 2nd,2008
• Cancer Medicine 
  Chapter: Tumor Suppressor Genes 
  Park BH, Vogelstein BEditors: Holland and Frei.BC Decker, Hamilton OntarioEdition 6th,2003
• Join now to see all

Abstracts/Posters

• Cell versus Cell-Free Candidate Biomarkers
  Park BH, American Society of Clinical Oncology (ASCO) Annual meeting, Chicago, IL, 1/1/2014

Lectures

• Breast Cancer Mutations as Diagnostic and Therapeutic Targets for Therapy 
  University of North Carolina, Chapel Hill, NC - 1/1/2019
• Precision Breast Oncology: Genes to Drugs 
  The Mayan Riveria, Mexico - 1/1/2019
• Mutations in breast cancer as diagnostic and therapeutic targets 
  Baltimore, MD - 1/1/2018
• Germline v Somatic testing and the importance of Molecular Tumor Boards 
  White Oak, MD - 1/1/2018
• Breast cancer mutations as targets for therapy 
  Chicago, IL - 1/1/2018
• Breast cancer mutations as therapeutic and diagnostic targets 
  Moffitt Cancer Center, Tampa Bay, FL - 1/1/2018
• Circulating Tumor DNA to Guide Therapies for Early Stage Breast Cancer 
  Johns Hopkins School of Medicine, Baltimore, MD - 1/1/2018
• Research Integrity Colloquium 
  1/1/2018
• Precision Oncology: Using Science to Treat Patients 
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD - 1/1/2018
• Spliceosome mutations as targets for breast cancer therapy 
  Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD - 1/1/2018
• Targeting rare spliceosome mutations in breast cancer 
  Baltimore, MD - 1/1/2018
• Breast Cancer Research Foundation Prevention Think Tank, Biomarkers of Risk 
  New York, NY - 1/1/2018
• Precision Oncology: Using Science and Technology to Treat Individual Cancer Patients 
  Cambridge, MD - 1/1/2018
• Tumor Heterogeneity: Mixing things up. 
  Curacao - 1/1/2018
• Liquid Biopsies for Breast Cancer 
  Hamilton, Bermuda - 1/1/2018
• Circulating plasma tumor DNA as biomarkers for breast cancer therapy 
  University of Maryland, Baltimore, MD - 1/1/2017
• Revolutionizing cancer diagnosis 
  Bethesda MD. - 1/1/2017
• Circulating cell-free plasma tumor DNA: Applications for Breast Oncology 
  University of Washington, Seattle, WA - 1/1/2017
• Precision therapy for breast cancer: Ending overtreatment and undertreatment. 
  University of Washington, Seattle, WA - 1/1/2017
• Targeting spliceosome mutations for breast cancer therapy 
  Dallas, TX - 1/1/2017
• Breast cancer mutations as diagnostic and therapeutic targets 
  New York, NY - 1/1/2017
• Breast cancer mutations for diagnostic and therapeutic applications 
  Vanderbilt Ingram Cancer Center, Nashville, TN, 2017; University of Michigan Comprehensive Cancer Ce - 1/1/2017
• Liquid biopsies for metastatic breast cancer 
  Houston, TX, 2017; New York, NY, 2017 - 1/1/2017
• Liquid biopsies to guide clinical decision in breast cancer 
  Komen of Maryland, Baltimore, MD - 1/1/2017
• Circulating plasma tumor DNA: Biomarkers for Precision Breast Oncology 
  Salisbury, MD - 1/1/2017
• Join now to see all

Other

• Guide 2 Chemo 
  Shockney L, Park BH
  http://www.guide2chemo.com/
  1/1/2009
• Mutations in cancer cells 
  Avon Foundation Breast Care Fund Presentation
  1/1/2007